Aswolinskiy, Witali
Munari, Enrico
Horlings, Hugo M.
Mulder, Lennart
Bogina, Giuseppe
Sanders, Joyce
Liu, Yat-Hee
van den Belt-Dusebout, Alexandra W.
Tessier, Leslie
Balkenhol, Maschenka
Stegeman, Michelle
Hoven, Jeffrey
Wesseling, Jelle
van der Laak, Jeroen
Lips, Esther H.
Ciompi, Francesco
Funding for this research was provided by:
Dutch Cancer Society (11917)
HORIZON EUROPE Innovative Europe (825292)
Article History
Received: 3 February 2023
Accepted: 2 October 2023
First Online: 13 November 2023
Declarations
:
: The use of the slides from RUMC for the study was approved by the Ethical Committee of the Radboud University Medical Center (2020-7103). The use of the slides from NKI for the study was approved by the institutional review board of the Netherlands Cancer Institute under number CFMPB737. The use of the slides from SCDC for the study was approved by the Ethic Committee for Clinical Research of the Provinces of Verona and Rovigo under number 25046. The TCGA slides used for training the segmentation model are publicly available, and therefore, ethical approval is not applicable.
: Not applicable.
: FC was Chair of the Scientific and Medical Advisory Board of TRIBVN Healthcare, France, and received advisory board fees from TRIBVN Healthcare, France, in the last five years. He is shareholder of Aiosyn BV, the Netherlands. MB is medical advisor at Aiosyn BV. All other authors declare no conflict of interest. JvdL was a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last five years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands.